PMID- 20136782
OWN - NLM
STAT- MEDLINE
DCOM- 20101022
LR  - 20100719
IS  - 1365-3148 (Electronic)
IS  - 0958-7578 (Linking)
VI  - 20
IP  - 4
DP  - 2010 Aug 1
TI  - Establishment of platelet donor registry improves the treatment of platelet 
      transfusion refractoriness in Guangzhou region of China.
PG  - 269-74
LID - 10.1111/j.1365-3148.2010.00995.x [doi]
AB  - Platelet transfusion refractoriness (PTR) is the major complication of long-term 
      platelet supportive care. To improve the effectiveness of platelet transfusion 
      therapy in PTR patients, we aimed to establish a platelet donor registry in our 
      region (Guangzhou, China) by typing the human leukocyte antigen (HLA) and human 
      platelet antigen (HPA). Blood donors (n = 864) from our population were genotyped 
      for HLA-A, HLA-B and HPA systems by polymerase chain reaction amplification with 
      sequence-specific primer(PCR-SSP) techniques. Using this cohort, we compared the 
      results of platelet transfusions (matched vs. random) in 23 patients with PTR. 
      Matched platelets were selected either by HLA antigen matching or by HLA antibody 
      matching, as predicted by antibody specificity prediction (ASP) analysis. 
      Significantly higher platelet recovery (PPR) values were obtained with 
      HLA-matched platelets in comparison with random platelets. No significant 
      difference in PPR was observed between HLA matching and ASP methods. In two 
      patients, platelet-specific alloantibodies (alloabs) (anti-HPA-3b and 
      anti-HPA-5b) were detected besides HLA class I alloabs. Transfusion with HLA- and 
      HPA-compatible platelets in both the patients resulted in significantly higher 
      PPR when compared with HLA-compatible platelet transfusion alone. In this study, 
      we demonstrated that the establishment of an HLA- and HPA-typed platelet 
      aphaeresis donor registry is useful to improve the treatment outcome of PTR 
      patients and to maintain a long-term platelet transfusion strategy.
FAU - Xia, W J
AU  - Xia WJ
AD  - Institute of Blood Transfusion, Guangzhou Blood Center, Guangzhou, Guangdong 
      510095, China.
FAU - Ye, X
AU  - Ye X
FAU - Tian, L W
AU  - Tian LW
FAU - Xu, X Z
AU  - Xu XZ
FAU - Chen, Y K
AU  - Chen YK
FAU - Luo, G P
AU  - Luo GP
FAU - Bei, C H
AU  - Bei CH
FAU - Deng, J
AU  - Deng J
FAU - Santoso, S
AU  - Santoso S
FAU - Fu, Y S
AU  - Fu YS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100204
PL  - England
TA  - Transfus Med
JT  - Transfusion medicine (Oxford, England)
JID - 9301182
RN  - 0 (Antigens, Human Platelet)
RN  - 0 (Autoantibodies)
RN  - 0 (HLA Antigens)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Antigens, Human Platelet/genetics
MH  - Autoantibodies/blood
MH  - *Blood Donors
MH  - China
MH  - DNA/genetics
MH  - Gene Frequency
MH  - Genes, MHC Class I
MH  - Genotype
MH  - HLA Antigens/genetics
MH  - Humans
MH  - Platelet Count
MH  - *Platelet Transfusion
MH  - *Registries
MH  - Thrombocytopenia/etiology/*therapy
EDAT- 2010/02/09 06:00
MHDA- 2010/10/23 06:00
CRDT- 2010/02/09 06:00
PHST- 2010/02/09 06:00 [entrez]
PHST- 2010/02/09 06:00 [pubmed]
PHST- 2010/10/23 06:00 [medline]
AID - TME995 [pii]
AID - 10.1111/j.1365-3148.2010.00995.x [doi]
PST - ppublish
SO  - Transfus Med. 2010 Aug 1;20(4):269-74. doi: 10.1111/j.1365-3148.2010.00995.x. 
      Epub 2010 Feb 4.